Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.
De Filippi, Rosaria
Eur J Haematol
MetadataShow full item record
Corazzelli, G., Frigeri, F., Arcamone, M., Aloj, L., Capobianco, G., Becchimanzi, C., Morelli, E., et al. (2011). Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.. Eur J Haematol, 87 (6), 547-553. https://doi.org/10.1111/j.1600-0609.2011.01683.x
Patients with recurring T-cell non-Hodgkin lymphoma (T-NHL) are incurable and candidate for investigational agents. Here, we report on five patients with T-NHL refractory to multiple chemotherapy lines, including in all cases alkylators and gemcitabine, who received the third-generation chloroethylnitrosourea fotemustine at a dose of 120 mg/m(2) every 21 d, up to eight courses. Median actual dose intensity was 79%; toxicity was manageable and mainly hematological. One complete remission, one partial remission, two protracted disease stabilization, and one transient, minor response were achieved. Time to progression ranged from 48 to 240+ d. This is the first evidence ever reporting the activity of fotemustine in end-stage T-NHL. Formal studies with this agent are warranted in T-cell malignancies.
Humans, Lymphoma, T-Cell, Nitrosourea Compounds, Organophosphorus Compounds, Antineoplastic Agents, Alkylating, Aged, Middle Aged
External DOI: https://doi.org/10.1111/j.1600-0609.2011.01683.x
This record's URL: https://www.repository.cam.ac.uk/handle/1810/287417
Publisher's own licence